-Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Top Cited Papers
Open Access
- 4 November 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (2), 167-174
- https://doi.org/10.1093/cid/cir790
Abstract
(See the Editorial Commentary by Perez and Bonomo, on pages 175–7 .) Background. Extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems—considered the drugs of choice—are needed because of the emergence of carbapenemase-producing enterobacteria. The efficacy of ß-lactam/ß-lactam inhibitors (BLBLI) in such infections is controversial. Methods. The authors performed a post hoc analysis of patients with bloodstream infections due to ESBL-EC from 6 published prospective cohorts. Mortality and length of hospital stay in patients treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ]) or carbapenem were compared in 2 cohorts: the empirical therapy cohort (ETC) and the definitive therapy cohort (DTC). Confounding was controlled by multivariate analysis; for patients in the ETC, a propensity score for receiving carbapenem was also used. Results. The ETC included 103 patients (BLBLI, 72; carbapenem, 31), and the DTC included 174 (BLBLI, 54; carbapenem, 120). Mortality rates at day 30 for those treated with BLBLI versus carbapenems were 9.7% versus 19.4% for the ETC and 9.3% versus 16.7% for the DTC, respectively (P > .2, log-rank test). After adjustment for confounders, no association was found between either empirical therapy with BLBLI (adjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], .29–4.40; P = .84) or definitive therapy (adjusted HR, 0.76; 95% CI, .28–2.07; P = .5) and increased mortality. Furthermore, BLBLI therapy, with respect to carbapenem, was not found to influence length of hospital stay. Conclusions. These results suggest that AMC and PTZ are suitable alternatives to carbapenems for treating patients with bloodstream infections due to ESBL-EC if active in vitro and would be particularly useful as definitive therapy.This publication has 40 references indexed in Scilit:
- Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infectionsInternational Journal of Antimicrobial Agents, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Enterobacter cloacae : Role of Carbapenem TherapyAntimicrobial Agents and Chemotherapy, 2010
- Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)Antimicrobial Agents and Chemotherapy, 2010
- Bacteraemia due to extended-spectrum -lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcomeJournal of Antimicrobial Chemotherapy, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial TreatmentAntimicrobial Agents and Chemotherapy, 2007
- Endocarditis Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae : Emergence of Resistance to Ciprofloxacin and Piperacillin-Tazobactam during Treatment despite Initial SusceptibilityAntimicrobial Agents and Chemotherapy, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987